Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. - Wikidata - awgldk - TriplyDB

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

http://www.wikidata.org/entity/Q44787272

about

Teriflunomide for multiple sclerosis Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis Teriflunomide and its mechanism of action in multiple sclerosis.A changing treatment landscape for multiple sclerosis: challenges and opportunities.Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.Teriflunomide for multiple sclerosis in real-world setting.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Predictive value of early brain atrophy on response in patients treated with interferon β Imaging outcome measures for progressive multiple sclerosis trials Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.

P2860

Q24186016-E5D51E37-AFF6-4328-97D2-D830C73ACB52 Q30965003-91498B2D-A691-4B75-84EC-0EE02F333FCA Q33692589-DF42E115-DFD2-4244-B903-3A8F08048522 Q35211079-81595879-D3FA-4562-98B5-75214AF4FA3C Q36670128-B74F5F60-F5FD-41C7-A93E-C17C18165754 Q37097159-F3C74E95-7353-436D-B625-3CD9F54E9187 Q37300066-E4D8025E-C4B1-411F-A2DB-984363D213B4 Q37320255-EF0128E3-D882-4AB4-A040-65838EB013FB Q37730005-982CFBE7-4B13-40DC-A429-BFE29B636732 Q38180166-FE385D38-28C6-4367-B2DE-3D57EA36D06E Q38205268-A5C661F1-3F58-44F0-8DCE-24992FBA3A65 Q38289353-B1FA6333-21DB-4A91-B5DD-F5A32E500A57 Q38371842-F44B78F8-3239-4D4C-B900-F24B2C33EBCA Q38891855-1C450432-04AB-4A8D-A22F-F1FEDF03A25F Q39032639-AD3D428D-B984-49E3-A64C-36357EAF4F5A Q41197913-A4F0BE74-59CC-4103-B925-87FF8BE08752 Q42660399-B1D4BB8C-9B15-4159-BE7B-FFA3738C622A Q47967971-3840BEF2-8ED7-41D9-9F46-C8EE0CDD8407 Q48770738-1278FFCF-9C1F-4684-9C4E-A8A09692903F

P2860

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

http://www.wikidata.org/entity/Q44787272

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@en

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@nl

type

label

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@en

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@nl

prefLabel

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@en

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@nl

P1433

Q44787272-7BC1C7FD-472E-4937-BB0F-85E667979A1F

P1476

Q44787272-C277459F-14E6-47CB-825A-EF472E0B940F

P2093

Q44787272-0C10096B-D74A-413E-A483-7C7B072D85F5

Q44787272-124BF3C4-C357-4DD1-B08C-136AA17D9109

Q44787272-1FFB6623-D990-43A5-A427-70129B5E0953

Q44787272-27CE6FC8-D75E-4616-BCBB-23D094FCD0C8

Q44787272-2FAFEF76-3AF5-4996-8378-AC76F906B144

Q44787272-40C2C87D-92B3-4FBF-8BF7-D2DDC019823B

Q44787272-4B26002C-CC3A-4A8F-A98A-652007990E1E

Q44787272-8410F3F9-52C1-42AA-AA3A-BEFD41F1CDDF

Q44787272-977AE9D6-1C78-4EC5-8629-F04F9FA7800C

Q44787272-BDED5B18-7BFC-4063-991D-A43F5A586C02

P2860

Q44787272-0671F6A2-59C7-4F51-B7CC-B3E35C28A13E

Q44787272-0A63F901-46BE-45AF-B471-3B51D8229132

Q44787272-21EF0023-E533-40E6-AD5D-EE0754AB4EA0

Q44787272-22EEFFA9-7C1C-4121-A1F2-7773F6C9CDB0

Q44787272-268F4DBE-F0E4-482B-B914-B86A313E74B8

Q44787272-32338589-CEDE-437D-94DD-EF7226EF472E

Q44787272-33A7A525-918B-4AD0-A4DC-0E99B0F15FB4

Q44787272-3C2FA6E9-3BAB-477B-AD79-403FAA845BC4

Q44787272-51489173-F0DA-4C0B-B9FC-4E8BA70EDC31

Q44787272-60DECB3D-F9CC-411F-9BDC-9B4FED22FDEB

P304

Q44787272-5B0D600C-4975-4261-A0B0-E92603A3B82D

P31

Q44787272-CA28963F-38BD-4049-A8AD-5018AFB28BCA

P356

Q44787272-F1A663FB-6A83-4FCA-8CF7-788D34F34D5F

P433

Q44787272-648E6517-1C5E-42CD-8D65-C67EDB79FA4A

P478

Q44787272-FD202BB9-5228-45F9-AA43-5CC94865CFD8

P50

Q44787272-722D46BC-8714-4147-8C46-6E3D690D313C

Q44787272-BD251E5D-B468-4854-B591-7DB0FE26F6B9

P577

Q44787272-FABEEC01-2C03-4E16-86E6-C93A755CB4D8

P5875

Q44787272-E8D1A0A5-E5A6-45CA-86D1-6569004F8543

P698

Q44787272-9347B6CF-CD5C-4D99-A293-0CB4B236A92B

P921

Q44787272-5A662132-E82A-47EF-A3BC-12DA00F02B21

Q44787272-E9CD509F-2F4B-4DFD-9FEA-AD88CC185DA4

P356

1352458513475723

P1433

Multiple Sclerosis Journal

P1476

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

@en

P2093

Aaron Miller

http://www.w3.org/2001/XMLSchema#string

Christian Confavreux

http://www.w3.org/2001/XMLSchema#string

Flavia Nelson

http://www.w3.org/2001/XMLSchema#string

Jerry S Wolinsky

http://www.w3.org/2001/XMLSchema#string

Lin Wang

http://www.w3.org/2001/XMLSchema#string

Mark S Freedman

http://www.w3.org/2001/XMLSchema#string

Paul O'Connor

http://www.w3.org/2001/XMLSchema#string

Philippe Truffinet

http://www.w3.org/2001/XMLSchema#string

Ponnada A Narayana

http://www.w3.org/2001/XMLSchema#string

Sushmita Datta

http://www.w3.org/2001/XMLSchema#string

P2860

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation.

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.

Composite MRI scores improve correlation with EDSS in multiple sclerosis

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry.

Pathophysiology of multiple sclerosis and the place of teriflunomide.

P304

1310-1319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458513475723

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235750596

http://www.w3.org/2001/XMLSchema#string

P698

23447359

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

multiple sclerosis